TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25219292

Group type: EXPERIMENTAL
Intervention: Idursulfase beta (0.5mg/kg/week) administered intravenously for 52 weeks
Number of subjects: 6
Study: 25220020

Group type: EXPERIMENTAL
Intervention: Oral delta-9-tetrahydrocannabinol (THC) treatments
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ad libitum cannabis smoking
Number of subjects: 11
Study: 25220528

Group type: EXPERIMENTAL
Intervention: Pulse pressure variation (PPV)-guided fluid therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 98
Study: 25220574

Group type: EXPERIMENTAL
Intervention: High-dose intravenous ascorbic acid (AA) at doses of 5, 30, and 60 g
Number of subjects: 10
Study: 25221331

Group type: EXPERIMENTAL
Intervention: CIED replacement with or without planned lead addition or revision
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: REPLACE DARE Score
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: DARE=0
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: DARE=7
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Hazard ratio for each change of 1 DARE unit
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Cox regression analysis
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 1744
Study: 25221334

Group type: EXPERIMENTAL
Intervention: 3-dimensional navigational model guided lead delivery for LV leads
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 3-dimensional navigational model guided lead delivery for RV leads
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clinical response criteria
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 31
Study: 25221606

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2,000 I.U. daily for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25222119

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) prophylaxis for PMTCT or triple antiretroviral treatment in pregnancy
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: CD4 count
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Gravidity
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Antiretroviral regimen (adjusted for age and gravidity)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) or triple ARVs
Number of subjects: 408
Study: 25222129

Group type: EXPERIMENTAL
Intervention: Synthetic cannabinoids (SCs) use in the last month
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Factors associated with SC use
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: SC use before and after federal ban
Number of subjects: 1080
Study: 25222841

Group type: EXPERIMENTAL
Intervention: Cabergoline treatment
Number of subjects: 24
Study: 25223394

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg) administered subcutaneously every other week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 160 mg loading dose of adalimumab
Number of subjects: 30
Study: 25223501

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 9
Study: 25223531

Group type: EXPERIMENTAL
Intervention: Healthcare-funded continuous glucose monitoring system (RT-CGMS)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Self-monitoring blood glucose (SMBG) only
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: RT-CGMS
Number of subjects: 149
Study: 25224002

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Number of subjects: 95
Study: 25224267

Group type: EXPERIMENTAL
Intervention: Immune cell populations in psoriatic adipose tissue
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CD16+CD56(Lo) NK cell population
Number of subjects: 30
Study: 25224611

Group type: EXPERIMENTAL
Intervention: Mock clinical trial (MCT) for adolescents (aged 15-17)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Mock clinical trial (MCT) for young adult women (aged 18-21)
Number of subjects: 135
Study: 25224748

Group type: EXPERIMENTAL
Intervention: Shorter time-to-process (less than 7 h)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Shorter resting-time (less than 2 h)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Longer stimulation-time (overnight)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fresh whole blood
Number of subjects: 22
Study: 25224842

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance testing (OGTT) with 300 ml of glucose-containing fluid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mixed-meal tolerance testing (MMTT) with 237 ml of fat/protein/carbohydrate-containing fluid
Number of subjects: 30
Study: 25225206

Group type: EXPERIMENTAL
Intervention: Bioencapsulated ACE2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bioencapsulated Ang-(1-7)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination therapy with ACE2 and Ang-(1-7)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bioencapsulated ACE2 or Ang-(1-7) in reversal protocol
Number of subjects: 100
Study: 25225420

Group type: EXPERIMENTAL
Intervention: Single-agent carfilzomib (56 mg/m2)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Carfilzomib plus low-dose dexamethasone (45 or 56 mg/m2)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Single-agent carfilzomib (70 mg/m2)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Single-agent carfilzomib (20 to 56 mg/m2)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Carfilzomib (various doses)
Number of subjects: 55
Study: 25225437

Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg
Number of subjects: 144
Study: 25225676

Group type: EXPERIMENTAL
Intervention: DNA vaccines (4 mg administered intramuscularly by Biojector at weeks 0, 4, and 8, with a homologous boost at or after week 32)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA vaccines (4 mg administered intramuscularly by Biojector)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fourth DNA vaccination
Number of subjects: 0
Study: 25225962

Group type: EXPERIMENTAL
Intervention: NaviAid G-EYE balloon-colonoscope
Number of subjects: 47
Study: 25226293

Group type: EXPERIMENTAL
Intervention: Exogenous kisspeptin (0.24 nmol/kg) administered intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GnRH (75 ng/kg) administered intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exogenous GnRH (25 ng/kg sc every 2 h for six days)
Number of subjects: 12
Study: 25226407

Group type: EXPERIMENTAL
Intervention: 20 g ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 25226426

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 39
Study: 25227179

Group type: EXPERIMENTAL
Intervention: High saturated fat diet + 3.45 g/d of docosahexaenoic acid (DHA) for 8 weeks
Number of subjects: 23
Study: 25227334

Group type: EXPERIMENTAL
Intervention: 2-msec light flashes given every 30 sec during sleep (n = 6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Darkness (control group, n = 7)
Number of subjects: 13
Study: 25227476

Group type: EXPERIMENTAL
Intervention: Pioglitazone (a thiazolidinedione)
Number of subjects: 0
Study: 25227629

Group type: EXPERIMENTAL
Intervention: Participants with a history of or current anogenital warts (AGW)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Participants with no history of anogenital warts (AGW)
Number of subjects: 600
Study: 25228283

Group type: EXPERIMENTAL
Intervention: Draf IIa frontal sinus surgery
Number of subjects: 63
Study: 25228850

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 25229334

Group type: EXPERIMENTAL
Intervention: Burnt sugarcane harvesting
Number of subjects: 28
Study: 25230375

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation-plus-extracorporeal CO2 removal
Number of subjects: 46

Group type: COMPARATOR
Intervention: Noninvasive ventilation-only
Number of subjects: 46
Study: 25230939

Group type: EXPERIMENTAL
Intervention: Tdap5 (Adacel) vaccine administered to 10-year-olds
Number of subjects: 1291
Study: 25231271

Group type: EXPERIMENTAL
Intervention: InTEM test
Number of subjects: 148

Group type: COMPARATOR
Intervention: ACT measurement
Number of subjects: 148
Study: 25232260

Group type: EXPERIMENTAL
Intervention: Anti-mycotic therapy based on the developed algorithm
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Detection of Candida species in bile samples
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Independent risk factors for biliary candidiasis
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Detection of azole-resistant Candida subspecies
Number of subjects: 127
Study: 25232828

Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Historical outcomes in unselected patients
Number of subjects: 23
Study: 25233155

Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 1532
Study: 25233248

Group type: COMPARATOR
Intervention: qEEG ratio of delta to alpha frequency power
Number of subjects: 385

Group type: COMPARATOR
Intervention: qEEG ratio
Number of subjects: 385

Group type: COMPARATOR
Intervention: qEEG ratio ≤10.5 among patients not taking benzodiazepines
Number of subjects: 385

Group type: COMPARATOR
Intervention: Routine PSG measures
Number of subjects: 385

Group type: COMPARATOR
Intervention: Obstructive sleep apnea
Number of subjects: 385
Study: 25233297

Group type: EXPERIMENTAL
Intervention: Dexcom G4
Number of subjects: 38

Group type: COMPARATOR
Intervention: Enlite
Number of subjects: 38
Study: 25234438

Group type: EXPERIMENTAL
Intervention: Intensity-modulated total marrow irradiation (TMI) at 3 Gy (n=3)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intensity-modulated total marrow irradiation (TMI) at 6 Gy (n=3)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intensity-modulated total marrow irradiation (TMI) at 9 Gy (n=6)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intensity-modulated total marrow irradiation (TMI) at 12 Gy (n=2)
Number of subjects: 14
Study: 25234476

Group type: EXPERIMENTAL
Intervention: Stroke patients with dysphagia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Stroke patients without dysphagia
Number of subjects: 74

Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Presence of dysphagia
Number of subjects: 74
Study: 25234930

Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m2 at first infusion and 250 mg/m2 subsequently) combined with cisplatin (80 mg/m2, triweekly) and capecitabine (2,000 mg/m2, triweekly for 2 weeks)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with cisplatin and capecitabine
Number of subjects: 47
Study: 25236503

Group type: EXPERIMENTAL
Intervention: 3 Ms (Medication, Meter, and Meals) intervention
Number of subjects: 5
Study: 25236513

Group type: EXPERIMENTAL
Intervention: CMR markers of myocardial damage (Infarct Size - IS, Microvascular Obstruction - MO)
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: CMR markers of myocardial damage (IS and MO)
Number of subjects: 738
Study: 25236780

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Ongoing medical management
Number of subjects: 342
Study: 25236899

Group type: EXPERIMENTAL
Intervention: Trachway assistance with a preformed nasotracheal tube
Number of subjects: 0
Study: 25236916

Group type: EXPERIMENTAL
Intervention: IgPro20 (subcutaneous immunoglobulin)
Number of subjects: 24

Group type: COMPARATOR
Intervention: IVIG (intravenous immunoglobulin)
Number of subjects: 24
Study: 25236917

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg once daily (n = 122)
Number of subjects: 202

Group type: COMPARATOR
Intervention: placebo (n = 80)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: linagliptin (without sulfonylureas)
Number of subjects: 202
Study: 25236982

Group type: EXPERIMENTAL
Intervention: Bavituximab plus paclitaxel and carboplatin
Number of subjects: 49
Study: 25237810

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25238535

Group type: EXPERIMENTAL
Intervention: PEG-IFN α-2a plus ribavirin
Number of subjects: 2347

Group type: COMPARATOR
Intervention: Genotype 2
Number of subjects: 2347

Group type: COMPARATOR
Intervention: Genotype 3
Number of subjects: 2347
Study: 25239224

Group type: EXPERIMENTAL
Intervention: Ridaforolimus-trastuzumab
Number of subjects: 34
Study: 25239228

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily after HSCT for 12 cycles (28 days each).
Number of subjects: 22
Study: 25239440

Group type: EXPERIMENTAL
Intervention: Chronic Granulomatous Disease (CGD) patients
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 41
Study: 25239610

Group type: EXPERIMENTAL
Intervention: MK-2206 60 mg QOD
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MK-2206 200 mg QW
Number of subjects: 71
Study: 25240075

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 437
Study: 25240112

Group type: EXPERIMENTAL
Intervention: Presence of lipid-rich necrotic core (LRNC)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Smoking prevalence among adults with LRNC
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Mean percent lumen area
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Normalized mean wall area
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Maximum wall area
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Percent lumen area in cross-sectional images with LRNC
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Normalized mean wall thickness in cross-sectional images with LRNC
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Normalized maximum wall thickness in cross-sectional images with LRNC
Number of subjects: 303
Study: 25240453

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: On-treatment LDL-C levels <70 mg/dl
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: On-treatment LDL-C levels ≥70 mg/dl
Number of subjects: 1039
Study: 25240525

Group type: EXPERIMENTAL
Intervention: REPAIR group (standardized aortic valve repair technique with expansible aortic ring annuloplasty)
Number of subjects: 261

Group type: COMPARATOR
Intervention: CVG group (mechanical composite valve and graft replacement)
Number of subjects: 261
Study: 25240540

Group type: EXPERIMENTAL
Intervention: Late/very late DES thrombosis cases
Number of subjects: 492
Study: 25241909

Group type: EXPERIMENTAL
Intervention: CB COPD
Number of subjects: 3
Study: 25241933

Group type: EXPERIMENTAL
Intervention: Procalcitonin clearance (PCT-c) measured at diagnosis, 24 hours, and 48 hours
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Δ Sequential Organ Failure Assessment (SOFA) score measured at ICU admission and after 48 hours
Number of subjects: 130
Study: 25242374

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m(2)) with trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m(2)) with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg tri-weekly doses)
Number of subjects: 12
Study: 25242417

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD) with 9 months of leuprolide and flutamide followed by off-treatment interval.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD) with longer time (≥ 60 days) to PSA rise after rise to T > 50 ng/dL.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time to first T > 50 ng/dL and PSA doubling time.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific intervention mentioned.
Number of subjects: 0
Study: 25242443

Group type: EXPERIMENTAL
Intervention: Preferred contact method (text messaging, e-mail, or any)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Landline phone as contact method
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Preferred contact other than phone
Number of subjects: 542

Group type: COMPARATOR
Intervention: Having a landline phone
Number of subjects: 542
Study: 25242890

Group type: EXPERIMENTAL
Intervention: Standard care plus SPC enriched with a standardized psychological intervention for patients and caregivers at home
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 340
Study: 25243015

Group type: EXPERIMENTAL
Intervention: Screening for STIs (Chlamydia trachomatis, Neisseria gonorrhea, syphilis, Trichomonas vaginalis)
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: Incident STIs over a 24 month period
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: Risk factors for incident STIs
Number of subjects: 2293
Study: 25243350

Group type: EXPERIMENTAL
Intervention: Patient-centered decision support notifications delivered via a personalized health record (PHR)
Number of subjects: 584
Study: 25243446

Group type: EXPERIMENTAL
Intervention: Transfusion of CMV-seronegative and leukoreduced blood
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Maternal breast milk feeding
Number of subjects: 539
Study: 25243564

Group type: EXPERIMENTAL
Intervention: Parietal peritoneum (PP) used as an autologous substitute for venous reconstruction during HPB surgery.
Number of subjects: 30
Study: 25243573

Group type: EXPERIMENTAL
Intervention: Standard care intervention
Number of subjects: 2017
Study: 25245327

Group type: EXPERIMENTAL
Intervention: High-dose interleukin-2 (HD-IL-2) at a dose of 18 MIU/m2/day by continuous IV infusion for 72 hours, repeated every 3 weeks for up to 4 cycles and then every 4 weeks for a further 2 cycles.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster radiotherapy (XRT) at 6-12 Gy administered in three daily doses on days -3 to -1 before the first and third cycle of IL-2.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of HD-IL-2 and XRT.
Number of subjects: 0
Study: 25245624

Group type: EXPERIMENTAL
Intervention: Adalimumab 160 mg at the start, 80 mg 2 weeks later, followed by 40 mg every other week for 52 weeks (with some patients increasing to 80 mg every other week)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 20
Study: 25245629

Group type: EXPERIMENTAL
Intervention: Infliximab monotherapy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Combination therapy with azathioprine
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Patients with increased baseline levels of CRP
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Patients evaluable for mucosal healing (MH)
Number of subjects: 203
Study: 25246084

Group type: EXPERIMENTAL
Intervention: Early survivors with cardiogenic shock (CS)
Number of subjects: 3670

Group type: COMPARATOR
Intervention: Patients without cardiogenic shock (CS)
Number of subjects: 3670
Study: 25247300

Group type: EXPERIMENTAL
Intervention: Carriage isolates of Neisseria meningitidis
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Meningococcal vaccines targeting fHbp
Number of subjects: 268
Study: 25248302

Group type: EXPERIMENTAL
Intervention: MEMS adherence monitoring
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Predictors of adherence
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Self-reported adherence predictors
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Psychological predictors
Number of subjects: 201
Study: 25248945

Group type: EXPERIMENTAL
Intervention: Oral artesunate (ARS) 100, 150, or 200 mg OD
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral artesunate (ARS)
Number of subjects: 23
Study: 25249005

Group type: EXPERIMENTAL
Intervention: 20-week Contemplative Self-Healing Program (guided meditation and cognitive-affective-behavioral learning)
Number of subjects: 0
Study: 25249760

Group type: EXPERIMENTAL
Intervention: Anterior graft location in the tibia
Number of subjects: 75
Study: 25250055

Group type: EXPERIMENTAL
Intervention: Acupoint application (AP)
Number of subjects: 200
Study: 25250715

Group type: EXPERIMENTAL
Intervention: Pemetrexed and cisplatin for 4 cycles, followed by pemetrexed maintenance for non-progressing patients
Number of subjects: 51
Study: 25250858

Group type: EXPERIMENTAL
Intervention: RO4929097 (20 mg daily, 3 consecutive days per week)
Number of subjects: 36
Study: 25251317

Group type: EXPERIMENTAL
Intervention: 1-h lower sleep duration after 200 days
Number of subjects: 441

Group type: COMPARATOR
Intervention: Baseline sleep duration
Number of subjects: 441
Study: 25253045

Group type: EXPERIMENTAL
Intervention: Oral panobinostat (30 mg single dose for core phase, then thrice-weekly for extension phase)
Number of subjects: 25
Study: 25253674

Group type: EXPERIMENTAL
Intervention: Single-cell mass cytometry analysis of immune responses
Number of subjects: 32
Study: 25253770

Group type: EXPERIMENTAL
Intervention: Selumetinib (AZD6244, ARRY-142886)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Ras pathway mutations
Number of subjects: 206

Group type: COMPARATOR
Intervention: KRAS mutations
Number of subjects: 206
Study: 25253883

Group type: EXPERIMENTAL
Intervention: PRT062070 (Cerdulatinib)
Number of subjects: 0
Study: 25254044

Group type: EXPERIMENTAL
Intervention: NRT (30 mg of cocoa polyphenols, 80 mg of soy isoflavones, and 2 gr of myo-inositol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25254070

Group type: EXPERIMENTAL
Intervention: IPT + TAU
Number of subjects: 49

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 49
Study: 25254563

Group type: EXPERIMENTAL
Intervention: Intraperitoneal catumaxomab (10, 20, 50, and 150 μg within 10 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intraperitoneal catumaxomab
Number of subjects: 32
Study: 25255931

Group type: EXPERIMENTAL
Intervention: SAFETY Program (cognitive-behavioral family intervention)
Number of subjects: 35
Study: 25256179

Group type: EXPERIMENTAL
Intervention: Presence of Intraplaque Hemorrhage (IPH)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Thin/Ruptured Fibrous Cap (FC)
Number of subjects: 113
Study: 25256186

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography performed immediately after ICU admission
Number of subjects: 0